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 3 
Abstract 4 
Background 5 
Chemotherapy-related side effects and their management in patients with Non-Hodgkin’s 6 
Lymphoma (NHL) are not well defined in developing countries, including Kenya. This needs 7 
addressing considering the high number of patients with cancer in these countries. 8 
Consequently, we sought to determine the common side effects of chemotherapy used to treat 9 
NHL in pediatric patients. and its implications.  10 
 11 
Methods 12 
Observational study conducted at the Kenyatta National Hospital in patients aged ≤15 years. 13 
Some data was collected by reviewing patients’ records admitted to the pediatric oncology 14 
ward, December-2016 to May-2017; and additional data was collected retrospectively 15 
(review of patients’ records with NHL, January-2014 to May-2017). Data were analyzed 16 
descriptively.  17 
 18 
Results 19 
Overall, out of the identified NHL patients (n=85), 93% (n=79) had chemotherapy-related 20 
side effects. The majority of patients suffered from side effects were managed; apart from  21 
23% and 24% of the documented anemia and hypersensitivity, respectively..  22 
 23 
Conclusions 24 
Whilst the majority of the reported side-effects were being managed, the lack of management 25 
of some side effects raises real concerns since this indicates either failure to manage or failure 26 
to document their management in patients’ records, both of which should be addressed 27 
appropriately to improve future care.  28 
 29 
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1 Introduction 32 
Childhood cancers are a continual concern worldwide as they are a major cause of death in 33 
children (1). This includes Kenya where childhood cancers accounted for 15% of all cancer 34 
admissions between 1998-2008 (2). Furthermore, only one in ten children survive their 35 
cancer in Kenya compared to seven out of ten or more in developed countries (3,4). Even if 36 
children do survive their cancer, there are concerns with chemotherapy-related adverse events 37 
which compromises patients’ health related quality of life when compared to children without 38 
cancer (4). 39 
 40 
Among childhood cancers, lymphomas are among the most common cancers originating from 41 
cells of the immune system.  They are divided into Hodgkin’s and Non-Hodgkin’s 42 
Lymphomas (NHL). NHL is more prevalent in children than in adults, and characterized by 43 
the presence of malignant white blood cells. NHL consists of 3 types; B-cell, T-cell and 44 
natural killer lymphocyte lymphomas (5). In a recent study in the Republic of Congo, the 45 
authors observed a higher proportion of B-cell non-Hodgkin's lymphoma, BL and  bcl-2 46 
expression cancers among identified NHL patients (6). 47 
 48 
NHL is the third most common cancer in children after leukemia and brain tumors; 49 
accounting for approximately 7% of all cancers in children below the age of 20 years in high 50 
income countries (7). Overall, over 90% of NHLs occur in lower and middle income 51 
countries (LMICs) (7), with BL appearing particularly prevalent in sub-Sahara Africa with 52 
prevalence rates 10 to 20 times higher than seen in the US (8). This can be of particular  53 
concern as healthcare resources are more limited in LMICs versus western countries (9). 54 
Furthermore, there are certain risk factors for cancers that are more prevalent in LMICs, 55 
which include infections such as HIV/AIDS (10). HIV/ AIDs is a particular issue in sub-56 
Sahara Africa, with rates as high as 24% in some African countries (11,12) although there are 57 
ongoing plans to eliminate HIV from infants born to infective mothers (13). The HIV 58 
prevalence in Kenya, is approximately 4.9% (14). According to the Canadian Cancer Society, 59 
males are more susceptible to NHL than females because of mutations on X-linked immune 60 
system genes which cause a syndrome called Wiskott-Aldrich that predisposes them to NHL 61 
(15). Females have two X-chromosomes; consequently,  the likelihood of being affected is 62 
typically lower (16). Chemotherapy is the most common mode of treatment for NHL with 63 
treatment undertaken in three phases: induction, consolidation and maintenance. There are 64 
various combinations of medicines that can be used to treat NHL. These include 65 
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cyclophosphamide, doxorubicin hydrochloride (Adriamycin), vincristine and prednisolone 66 
(CHOPP). Prednisolone is given to delay the onset of chemotherapy-induced emesis. 67 
Sometimes patients are also given granulocyte colony stimulating factor (G-CSF) to 68 
accelerate bone marrow production of  white blood cells (5). Rituximab is also increasingly 69 
used to improve patient outcomes, particularly in higher income countries (7,18). The number 70 
of medicines, their dosages and duration of treatment depends on the type and stage of 71 
lymphoma.  with chemotherapy typically given in cycles followed by a resting period.  72 
Generally, each cycle lasts for several weeks (19). 73 
 74 
Despite their benefits, the various chemotherapy combinations, including CHOP, have acute 75 
and chronic side-effects. The most common side-effects include alopecia, nausea and 76 
vomiting, bone marrow suppression and a general reduction in patient’s quality of life. Some 77 
of these side effects are dose dependent and vary from one child to another, whilst others are 78 
common among all pediatric patients. The presence and severity of side effects also depends 79 
on patients’ ages, weight, body surface area and type of the chemotherapy.  Consequently, 80 
there is often a need for dose adjustments during prescribing (20,21). We are also aware that 81 
chemotherapy causes a reduction in  white blood cell count, especially neutrophils, which 82 
makes patients susceptible to secondary infections during their nadir period (22). This needs 83 
to be carefully monitored. Pain can also occur as a consequence of tissue destruction and 84 
invasion by cancerous cells, and it may also be a side effect of chemotherapy.  Typically pain 85 
is managed using analgesics in line with the WHO pain ladder (23).  86 
 87 
There are adverse effects with chemotherapy; however, their appropriate management can 88 
subsequent the morbidity and mortality (5, 24). Having said that, to date, very few studies 89 
have been undertaken regarding chemotherapy-associated side effects in paediatric patients 90 
with NHL in sub-Sahara Africa including Kenya. This is important given the extent of NHL 91 
in these countries and concerns with issues of affordability and availability of medicines to 92 
adequately diagnose and treat these patients as well as the side-effects of any chemotherapy. 93 
Consequently, we sought to determine the prevalence and types of chemotherapy-related side 94 
effects, and their management, among paediatric patients admitted to a leading public tertiary 95 
care hospital in Kenya, which typically manages these patients from across Kenya, to provide 96 
future guidance in Kenya and elsewhere across sub-Sahara Africa. 97 
 98 
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2 Patients and methods. 99 
2.1 Study site, design, and data collection  100 
This observational study was carried out at Kenyatta National Hospital (KNH), the largest 101 
national referral hospital in Kenya, which has a bed capacity of 1800 beds and has a 102 
specialized paediatric oncology unit where patients from across Kenya with NHL are 103 
diagnosed and treated. Data was collected using two approaches; firstly, a review of patients’ 104 
records who were admitted to the pediatric oncology ward from December-2016 to May-105 
2017; secondly, a retrospective review of patients’ records with NHL from the Records 106 
Department of the KNH hospital from January-2014 to May-2017, using a universal 107 
sampling technique involving all patients who had been diagnosed for NHL and had received 108 
chemotherapy.  109 
 110 
2.2 Study population, inclusion and exclusion criteria 111 
The inclusion criterion was all children aged ≤15 years, diagnosed and treated for NHL. 112 
Children with other comorbidities were excluded to ensure that the side effects recorded were 113 
mainly due to the administered chemotherapy.  114 
2.3 Outcome measures, study variables and sample size 115 
Predesigned data collection forms were used to obtain information from patients’ records 116 
diagnosed and treated for NHL. These forms were pre-tested to enhance the robustness of 117 
data collection. Data from the patients’ records admitted in the wards, was used to estimate 118 
the prevalence of NHL; whereas, data on the management of NHL patients (including 119 
adverse effects of chemotherapy and their management) was collected from all NHL patients 120 
identified through both approaches.  The collected information included patients’ biological 121 
data, age, weight, height and sex, time of diagnosis, drugs/regimen used, the side effects and 122 
any interventions made. The sample size was calculated using the following formula 123 
proposed by Cochran (25).  124 
N=Z2P (1-P) 125 
C2 126 
Where N=sample size 127 
Z= 1.96 128 
C= Confidence interval 129 
P=Prevalence  130 
Thus N= 1.962 * 0.07(1-0.07) 131 
                         0.052 132 
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=99.93636, Consequently we sought to analyse 100 patients with, as mentioned,  a universal 133 
sampling approach adopted. 134 
 135 
2.4 Data Analysis 136 
Descriptive statistics, mean and standard deviation for normally distributed continuous 137 
variables and frequencies and proportions for categorical variables, were used to describe 138 
patients’ characteristics and study outcomes. Data was presented using frequency distribution 139 
tables, graphs and pie charts as appropriate.  The prevalence was represented as proportions 140 
of patients with NHL to that of other cancers. Microsoft Excel and SPSS programs were used 141 
to analyze the data. 142 
 143 
2.5 Ethical Approval  144 
Ethical approval was sought from the KNH /University of Nairobi ethics and research review 145 
committee with a reference number UP898/11/2016.  Patients’ identities were not revealed 146 
and code numbers were used instead. Files were not taken out of the records department. The 147 
data collection forms were placed under lock and key, and the key was only accessed by the 148 
principal investigator. Data entered in Microsoft Excel and SPSS data was password 149 
protected. 150 
 151 
3 Results  152 
3.1 General 153 
Data collection was affected by nationwide doctors’ strike which took a period of 100 days 154 
from December 2016 to March 2017. As a result, patients were discharged to private 155 
hospitals resulting in very few patients in the paediatric oncology wards during the study 156 
period. This led to the initial sample size of (n=100) not being achieved. Consequently, two 157 
approaches were used for data collection: review  patients currently in the ward (n=12) and a 158 
retrospective review of  patients’ records from the records department (n=73); with both 159 
approaches identified  a total of 85 patients. 160 
 161 
3.2 Prevalence of Non-Hodgkin’s lymphoma and patient demographics 162 
A total of 85 paediatric patients with NHL were identified and reviewed out of which , the 163 
majority were male (79%) and aged 6-10 years old. The average weight of patients in the 164 
study was 23 kg (SD:±8.14) (Table 1). Out of the total number of children admitted to the 165 
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pediatric oncology wards at the time of data collection (n=73), 17% (n=12) had NHL while 166 
leukemia was the most common type of cancer with 33% (n=24). (Table 1). 167 
 168 
3.3 Clinical characteristics of the NHL paediatric patients  169 
The majority of the NHL patients (98%) were diagnosed both clinically (based on symptoms) 170 
and objectively (via the clinical investigations such as x-rays, CT scans and biopsies). The 171 
remaining 2% were diagnosed using laboratory assessment only consisting of complete blood 172 
counts, level of inflammatory markers and lactate dehydrogenase levels. All the patients went 173 
through the induction phase of treatment and out of these, 39% were still on the induction 174 
phase at the time of the study, 4% had finished induction and were in the consolidation phase 175 
while 57% had completed induction and consolidation and were on the maintenance phase. 176 
All the patients had gone through or were still in the first cycle of chemotherapy; 61% of 177 
patients were still in the consolidation phase together with those who had completed it, while 178 
56.5% were in the maintenance phase. The majority of the patients suffered from Non-179 
Burkitts lymphoma (52%) (Table 2). 180 
 181 
3.4 Management of Non-Hodgkin’s Lymphoma 182 
The various drug combinations that were used for the induction phase included 6 cycles of 183 
cyclophosphamide, vincristine, doxorubicin, prednisolone and procarbazine (CHOPP). Other 184 
drug combinations included CHOP+M (Cyclophosphamide, Vincristine, doxorubicin, 185 
methotrexate and prednisolone).  For the consolidation phase, cyclophosphamide, cytarabine 186 
and doxorubicin were administered in two cycles.  Much higher doses were typically used for 187 
the consolidation phase compared to the induction phase. Cyclophosphamide, doxorubicin, 188 
vincristine, methotrexate (both oral and intrathecal) and 6- mercaptopurine were used for the 189 
maintenance phase in 16 cycles. The various dosages of the medicines were adjusted 190 
according to the BSA (body surface area) of the children calculated using their weights and 191 
heights. This reduced their side effects due to body surface area variations (Appendix 1).  192 
 193 
For the relapse of BL, patients were treated with methotrexate, 6-mercaptopurine, vincristine 194 
and cytarabine. For the relapse of non-Burkitts lymphoma, patients were treated with 195 
methotrexate, doxorubicin and vincristine (Appendix 1). In two cases, patients were 196 
unresponsive to CHOP+M and were given vincristine, adriamycin, cytarabine and cisplatin 197 
(VAC-CIS) instead (26). 198 
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 199 
3.5 Side effects of cytotoxics used for treatment of NHL 200 
The most common side effects experienced by patients were vomiting (93%, n=79), followed 201 
by anaemia (<11.0g/dl) (88%, n=75), loss of appetite and weight (86%, n=73), pain (84%, 202 
n=71) and leucopenia (72%, n=61) (Figure 1). All these side effects were confirmed from 203 
patients’ files as related to the administered chemotherapy.  204 
 205 
3.6 Management of side effects of chemotherapy for paediatric patients with NHL 206 
The majority of patients who suffered from the chemotherapy-related side effects were 207 
receiving treatment (Table 3). All patients who suffered from loss of appetite, mucositis, 208 
diarrhea and hyperacidity were managed. It was noted that a number of patients who suffered 209 
from anemia and allergies were not treated for these side-effects. The specific management 210 
for each side effect is displayed in Table 4. 211 
 212 
The proportion of patients who were managed for pain was 94%, which was addressed using 213 
analgesics including opioids (morphine (14%), dihydrocodeine (25%), and tramadol (2%) as 214 
well as simple analgesics including paracetamol (47%), and NSAIDs: ibuprofen (9%) and 215 
diclofenac (1%). 216 
 217 
Leucopenia was experienced in 61 patients of whom 80% were managed using filgrastim 218 
administered within 24-72 hours post chemotherapy. However, details for the remaining 20% 219 
was not indicated in their files.  Patients may experience fever, which is a sign of infection 220 
accompanied with mucositis. In the study, 82% of the patients who had fever (Table 3) were 221 
given paracetamol and ibuprofen , (Table4).   222 
 223 
Various chemotherapy agents were withdrawn from the children due to the different side 224 
effects. Cyclophosphamide was withdrawn from one patient due to pleural effusion, 225 
doxorubicin due to cardiomyopathy shown on x-ray, vincristine due to an allergic reaction in 226 
one patient, 6- mercaptopurine and methotrexate due to anemia in two patients, adriamycin 227 
due to pancytopenias in two patients and in one case the dosages of 6- mercaptopurine and 228 
methotrexate were reduced due to anaemia.  In another case, cytarabine was used instead of 229 
methotrexate due to an allergic reaction which developed after administration. Generally, the 230 
allergic reactions were not specified in the patient files. 231 
 232 
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4 Discussion 233 
From our study findings, NHL was the second most common cancer in the pediatric oncology 234 
ward with a prevalence of 17% (Table 1). NHL was more common in male children than 235 
females in our study, which is similar to data from the American Cancer society which 236 
indicates that NHL is 2-3 times more common in boys than girls(27,28,). In Sub-Saharan 237 
Africa, higher incidences of lymphomas have also been  reported in males than females at 16 238 
and 10.8 per 100,000 children, respectively (29). As mentioned, this is perhaps a reflection of 239 
the mutation of the X-linked immune system genes (30). However, more research needs to be 240 
undertaken before we can say anything with certainty. 241 
 242 
Our study had more patients with Non-Burkitts Lymphoma than Burkitts lymphoma. This is 243 
different though to the majority of published studies which showed BL is more common in 244 
Sub-Saharan Africa due to presence of Epstein Barr virus responsible for its etiology (31), 245 
with an overall prevalence of 29.2 % in Kenya (32). However, this could be due to the small 246 
sample size of this study.  247 
 248 
The study findings indicated an appropriate and accurate diagnosis of NHL since the majority 249 
of patients were diagnosed clinically then confirmed via further investigations. In addition, 250 
the regimens used for the management of NHL is consistent with other settings (19).  This 251 
indicates that children are getting standard care, which is encouraging. The top three side 252 
effects of chemotherapy seen in our study were vomiting (93%), anemia (88%) and a loss of 253 
appetite (86%). This is similar to published figures from the American Cancer Society, where 254 
the most common side effects of chemotherapy in children are nausea and vomiting, hair loss, 255 
mouth sores, loss of appetite, diarrhea or constipation, low blood cell count and an increased 256 
risk of infection (26).  257 
 258 
Additionally, our findings showed that the interventions being given to the patients with the 259 
side effects were appropriate in line with published studies and standards (1,2,33), which is 260 
again encouraging considering the limited resources available in LMIC countries such as 261 
Kenya to adequately treat patients with  cancer (34). There have been concerns whether G-262 
CSF should be given prophylactically rather than after chemotherapy. However, more recent 263 
data suggests that giving G-CSF 24 to 72 hours after chemotherapy is effective in line with 264 
administration times in our study (35). All patients who had loss of appetite, mucositis, 265 
diarrhoea and acidity as side effects were managed appropriately for these (Table 4), 266 
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including nutritional supplementation, nutritional counseling to the mothers and nasogastric 267 
tubes to administer foods to patients who are unable to feed. However, not all of the patients 268 
who suffered from some other side effects including allergic reactions, anemia, leucopenia, 269 
fever, pain, dehydration, vomiting, hyponatremia and constipation, were subsequently 270 
managed appropriately. This could perhaps be either due to a lack of documentation although 271 
the intervention was given since the information was retrieved from the records and this was 272 
not recorded; alternatively, the intervention was not given at all. Failure to manage the side 273 
effects of chemotherapy for  mainly pancytopenia can lead to death due to excessive bleeding 274 
and infections. Consequently, this needs to be looked at further in this hospital to improve 275 
future care. Vomiting and diarrhea can lead to loss of fluids and electrolytes and patients may 276 
die due to hypovolemic shock. Consequently, it is also important to manage these side effects 277 
and record any interventions made (5). These concerns are now being followed up in the 278 
hospital, and will be the subject of future research. 279 
  280 
In our study, 94% of the patients with pain were managed using opioids: morphine, 281 
dihydrocodeine, as well as non-opioids: paracetamol, ibuprofen and diclofenac (Table 4). 282 
This finding is comparable to another study where the majority of the patients were treated 283 
effectively by non-opioid analgesics while others with bone and neuropathic pain were 284 
referred to specialists where pain was alleviated using strong opioid analgesics (36). The 285 
choice of analgesics was made according to the WHO pain ladder.  286 
 287 
Encouragingly, 80% of patients with leukopenia were managed with filgrastim in line with 288 
standard guidance (Table 4). This is encouraging as there can be concerns with the 289 
availability and affordability of medicines in countries such as Kenya generally as well as for 290 
medicines to treat patients with cancer (9,34,37). 291 
Overall, we believe this study contributes information on the management of NHL in children 292 
from low income settings such as Kenya.  Encouragingly, the findings have shown that 293 
diagnosis and management of NHL in children is generally undertaken according to the 294 
agreed standards and is consistent with care for NHL in children in other settings. KNH has 295 
cancer treatment guidelines that are consistent with international guidelines for treatment of 296 
different types of cancer. This is welcomed and encourages the hospital management team 297 
that the patients in KNH with NHL are getting good care, although there is still a need to 298 
strengthen some aspects of care to further improve patients’ outcomes. This includes patients 299 
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suffering from allergy, anemia, leucopenia and fever, and will be the subject of future 300 
research projects to address this 301 
The study had several limitations. Firstly, data collection was affected by a nationwide 302 
doctor’s strike which took place from December-2016 to March-2017. This led to fewer 303 
patients in the ward than expected and hence most patient details were retrieved 304 
retrospectively from the Records Department. Consequently, a sampling error due chance 305 
cannot be ruled out. 306 
 307 
Secondly, given the use of secondary information, some information may have been left out 308 
of patients’ notes such as other side effects including alopecia as well as the psychological 309 
effects of treatment including mood changes, anxiety, fatigue, and memory changes, which 310 
could not be observed. In addition, some of the information could not be obtained regarding 311 
the management of the side effects in some patients since it was not recorded in the files. The 312 
side effects might have been managed but not recorded in the files of patients.  Furthermore, 313 
although classic methods of evaluating adverse events usually include “grading” of these 314 
events, this data was not been included in this study as the grading information was typically 315 
not recorded in patients’ file only the occurrence of adverse events. Long term side-effects of 316 
chemotherapy were also not observed for example any adverse effect on sexual and 317 
reproduction issues as well as adverse effects on heart, brain, lungs, liver and kidneys. This 318 
was due to the limited period of study, and will be the subject of future research. Thirdly, the 319 
study was only conducted in one hospital in Kenya. However, this is the leading hospital in 320 
Kenya treating children from across Kenya with NHL. Despite these limitations, we believe 321 
our findings are valid and show concerns with the level of detail recorded in patients’ notes, 322 
which is now being followed up. 323 
 324 
5  Conclusions 325 
Non-Hodgkin lymphoma accounted for 17% of the total number of children admitted in 326 
pediatric oncology wards of a leading public tertiary care hospital in Kenya. Diagnosis and 327 
management of NHL were encouraging, given the issues of affordability and accessibility in 328 
the developing countries such as Kenya. The majority of the patients suffered from acute side 329 
effects of chemotherapy. Loss of appetite, mucositis, diarrhea and acidity were well managed. 330 
However, the management of anaemia and allergic reactions needs to be improved for the 331 
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patients to respond well to treatment and have better outcomes. Documentation should be 332 
emphasized and addressed in order to improve patients’ clinical outcome, including a greater 333 
focus on grading system for these events rather than just reporting their occurrence. A 334 
prospective large sample sized study is now being undertaken in KNH to corroborate our 335 
study findings and follow up on the outcomes of adverse events of chemotherapy on patients’ 336 
rate of hospitalization as well as potentially also mortality. The findings and their learnings 337 
can be used to further improve the management of NHL in this hospital including greater 338 
recognition and management of the side-effects of chemotherapy .  339 
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Tables 
0 
 
Table 1a: Prevalence of NHL in the paediatric ward at the time of data collection 
Type of cancer  Number of patients(n=72) 
n(%) 
Hodgkin’s lymphoma 
 
6 (8%) 
Non –Hodgkin’s lymphoma 
 
12 (17%) 
Leukemia 
 
24 (33%) 
 
Neuroblastoma 
7 (10%) 
 
Wilm’s tumor 
6 (8%) 
Nasal pharyngeal cancer 
 
4 (6%) 
Rhabdomyosarcoma 
 
4 (6%) 
Osteogenic sarcoma 7 (10%) 
Brain stem  glioma 2 (3%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Table 1b: Demographic characteristics of paediatric patients with Non-Hodgkin 
lymphoma (n=85). 
Variable Description 
Frequency 
n=85 Percent (%) 
Age(years) 
< 5 29 34.1 
6-10 39 45.9 
11-15 17 20 
Mean(SD) 7.3(2.99) 
Range(min, max) 10(3,13) 
Sex 
Male 67 78.8 
Female 18 21.2 
Weight(kg) 
Mean(SD) 23.03(8.136) 
Range(min, max) 44(10, 54) 
Height(cm) 
Mean(SD) 118.11(16.666) 
Range(min ,max) 73(75,148) 
 
 
Table 2: Clinical characteristics of paediatric patients with Non-Hodgkin Lymphoma at 
the Kenyatta National Hospital in Kenya. 
 
Variable Category/classification/description  
Frequency 
n=85 
Percent 
(%) 
Type of Lymphoma Burkitts Lymphoma 39 45.9 
  Non Burkitts Lymphoma 44 51.8 
  Burkitts relapse 1 1.2 
  Non Burkitts Relapse 1 1.2 
Diagnosis Methods Clinical and Laboratory assessment 83 97.6 
  Laboratory assessment Only 2 2.4 
Treatment Phases Induction 85 100.0 
  Consolidation 52 61.2 
  Maintenance 48 56.5 
Treatment Phases Combined Induction/Consolidation/maintenance 48 56.5 
  Induction and Consolidation 4 4.7 
  Induction Only 33 38.8 
0 
 
Table3: Comparison between the numbers of patients who experienced side effects of 
treatment versus those whose side effects were managed 
 
Side effect No. of patients experiencing 
having side effects (n=85) 
No. of patients whose side effects 
were managed 
 Percentage of 
patients managed  
Vomiting 79 75 95 
Anaemia 75 58 77 
Loss of  appetite 73 73 100 
Pain 71 67 94 
Leucopenia 61 49 80 
Dehydration 45 41 91 
Mucositis 44 44 100 
Hyponatremia 32 29 91 
Constipation 29 28 97 
Fever 28 23 82 
Diarrhea 21 21 100 
Acidity 18 18 100 
Allergic reactions  17 13 76 
0 
 
Table 4: Intervention given for the management of side effects of chemotherapy for 
Non-Hodgkin Lymphoma in paediatric patients at a Public tertiary care hospital in 
Kenya 
 
Side effect Intervention  
 
Vomiting Ondansetron or granisetron, metoclopramide and 
dexamethasone 
Anaemia Ranferon   and blood transfusion of packed red cells 
Loss of appetite Multivitamin syrup, counseling on high protein and 
lipid diet, predisure, ensure, vitalipid supplements and 
use of gastric tubes for those not able to feed properly. 
 
Pain Morphine, dihydrocodeine, paracetamol, ibuprofen and 
diclofenac 
Leucopenia  
 
 
Neupogen  
Dehydration  Normal saline  
Mucositis  Betadine mouth wash and miconazole gel  
Hyponatremia  Normal saline  
Constipation  Lactulose  
Fever  Paracetamol tablets and syrup, ibuprofen  
Diarrhea  ORS , zinc sulphate and loperamide 
Hyperacidity Omeprazole, esomeprazole and ulgel 
Cystitis  Mesna  
Secondary infections -chicken pox Acyclovir and calamine lotion  
Respiratory infections Amoxicillin Clavulanate 
Tinea capitis Clotrimazole cream 
Oral thrush Nystatin 
Insomnia  Midazolam 
 
0 
 
9 Appendix 1: Dose regimens used for management of Non-Hodgkin Lymphoma in 
Paediatrics at KNH. 
A. CHOP REGIMEN-currently protocol of choice for induction of remission in 
Burkitt’s Lymphoma at the KNH 
(i) INDUCTION 
DRUG DOSAGE 
Cyclophosphamide 
 
500mg/m2 IV on day 1 and weekly x6  
Adriamycin/Doxorubicin 
 
50mg/m2 IV on day 1, 21, and 43  
Vincristine 
 
1.4mg/m2 IV on day 1 and weekly X 6 
Prednisone 
 
40mg/m2 orally daily for 4 weeks tail off to zero from week 5 
Methotrexate 12.5mg/m2 IT twice weekly during induction and consolidation 
 
Consolidation starts 10-14 days after completing induction 
(ii) CONSOLIDATION 
DRUG DOSAGE 
Cyclophosphamide 
 
1200mg/m2 IV in saline over 8 hours on day 1 and 8  
Adriamycin/Doxorubicin 
 
60mg/m2 IV on day 1 
Cytarabine 
 
75mg/m2 SC days 1-4,22-25, 29-32 
*Second course is given after 7 to 10 days of day 8. This does not include Adriamycin 
Maintenance (24 months) starts 4 weeks after completing consolidation and is still remission 
(III) MAINTENANCE 
DRUG DOSAGE 
6-Mercaptopurine 
 
75mg/m2/ day ,PO on daily for 24 months  
Methotrexate 25mg/m2/week, PO weekly for 24 months. Rest period for two weeks in 
case of cytopenias for both 6MP and methotrexate 
Vincristine 
 
1.5mg/m2 IV on day 1 and monthly for 24 months 
IT MTX 
 
Every 8 weeks for 1st year for those without CNS disease 
Adriamycin 25mg/m2 every three months for 24 months 
 
Cyclophosphamide 300mg/m2 every three months 24 months 
 
 
In disease free events (continuing remission) this maintenance is continued for 24 months 
1 
 
B. CHOP-BLEO 
DRUG DOSAGE 
Cyclophosphamide 
 
1000mg/m2 IV on day 1 and weekly x 6  
Doxorubicin 
 
50mg/m2 IV on day 1, 21, and 43  
Vincristine 
 
2mg/m2 IV on days 1 and 5 and weekly x 6 
Prednisone 
 
40mg/m2 orally daily for 4 weeks tail off to zero from week 5 
Bleomycin 15 units IV on days 1 and 5 during induction and consolidation 
 
Methotrexate 12.5mg/m2 IT twice weekly during induction and consolidation 
 
 
1. Recurrent NHL before reaching maintenance may be re-induced using option B 
2. Older children 8-15 years with Non-Burkitt’s Non-Hodgkin’s Lymphoma are better 
suited for this option (B) 
If indeed remission is achieved, consolidation and maintenance should be as Acute 
Lymphocytic Leukemia. 
 
